Form 4: Intellia CSO Sells Shares for Tax Obligation
Insider Transaction Report
Intellia Therapeutics' Chief Scientific Officer, Birgit C. Schultes, reported a mandatory sale of 31 common shares to cover tax withholding obligations related to RSU vesting.
Summary
- Birgit C. Schultes, EVP, Chief Scientific Officer of Intellia Therapeutics, Inc. (NTLA), reported a transaction.
- On October 1, 2025, 31 shares of common stock were disposed of at a price of $17.38 per share.
- This transaction was a mandatory "sell-to-cover" to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).
- The sale was not a volitional trade by the reporting person.
- Following this transaction, Birgit C. Schultes beneficially owns 105,184 shares of common stock directly.
Sentiment
Score: 6
Explanation: The transaction is a routine, non-volitional 'sell-to-cover' for tax purposes, which is a neutral event. The executive retains a substantial holding, indicating continued alignment.
Positives
- The transaction is a mandatory tax-related sale, not a discretionary sale indicating a lack of confidence.
- The executive retains a significant beneficial ownership of 105,184 shares, demonstrating continued alignment with shareholder interests.
Negatives
- A reduction in direct beneficial ownership, even if for tax purposes, slightly decreases the executive's direct equity stake.
Future Outlook
NA
Management Comments
- Represents a mandatory 'sell-to-cover' transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on October 1, 2025, and does not represent a volitional trade by the Reporting Person.
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Birgit C. Schultes granted a Limited Power of Attorney to James Basta and Edward Dulac to execute and file SEC forms (Form ID, 3, 4, 5, Schedule 13D) on her behalf as an officer and/or director of Intellia Therapeutics, Inc. | 2025-01-13 | Streamlines compliance with Section 16 reporting requirements for the executive, ensuring timely and accurate filings. |
Stakeholder Impact
- Shareholders: Minimal direct impact as it's a small, non-volitional sale for tax purposes. The executive's continued significant holding suggests ongoing alignment.
- Employees: No direct impact.
Key Dates
| Date | Description |
|---|---|
| 2025-01-13 | Date of execution of the Limited Power of Attorney by Birgit C. Schultes. |
| 2025-10-01 | Date of the reported transaction (sale of common stock) and RSU vesting. |
| 2025-10-03 | Date the Form 4 was signed by the attorney-in-fact. |
Recommendation
holdThis Form 4 filing details a routine, mandatory 'sell-to-cover' transaction by a key executive to satisfy tax obligations upon RSU vesting. It is not a discretionary sale and therefore does not signal a change in management's confidence or the company's fundamentals. The executive retains a substantial equity stake. As such, this specific filing provides no new information that would warrant a change in investment thesis, leading to a 'hold' recommendation based solely on this report.
Keywords
Intellia Therapeutics, NTLA, Form 4, Insider Trading, Birgit C. Schultes, Sell-to-cover, RSU vesting, Executive compensation, Stock sale, Tax withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.